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We investigated whole-brain atrophy and ventricular enlargement over 18 months in nondemented
Parkinson’s disease (PD) and examined their associations with clinical measures and baseline CSF
markers. PD subjects (n ¼ 100) were classified at baseline into those with mild cognitive impairment
(MCI; PD-MCI, n ¼ 36) and no cognitive impairment (PD-NC, n ¼ 64). Percentage of whole-brain volume
change (PBVC) and ventricular expansion over 18 months were assessed with FSL-SIENA and ventricular
enlargement (VIENA) respectively. PD-MCI showed increased global atrophy (1.1%  0.8%) and
ventricular enlargement (6.9 %  5.2%) compared with both PD-NC (PBVC: 0.4  0.5, p < 0.01; VIENA:
2.1%  4.3%, p < 0.01) and healthy controls. In a subset of 35 PD subjects, CSF levels of tau, and Ab42/
Ab40 ratio were correlated with PBVC and ventricular enlargement respectively. The sample size
required to demonstrate a 20% reduction in PBVC and VIENA was approximately 1/15th of that required
to detect equivalent changes in cognitive decline. These findings suggest that longitudinal MRI
measurements have potential to serve as surrogate markers to complement clinical assessments for
future disease-modifying trials in PD.
 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).try, University of Cambridge
bridge Biomedical Campus,
44 1223 336968.
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Inc. This is an open access article1. Introduction
Up to 80% of Parkinson’s disease (PD) patients eventually
develop dementia (PD-D) (Aarsland et al., 2003). However, the
pathophysiological substrates of cognitive dysfunction leading up
to the demented state remain only partially understood (Nombela
et al., 2014; Williams-Gray et al., 2009; Winder-Rhodes et al.,
2013, 2015; Yarnall et al., 2013). In parallel with a recent shift to-
ward early interventions and the prospect of disease-modificationunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(Yarnall et al., 2015), there is an urgent need to identify surrogate
markers to track disease progression and perform risk-stratification
to improve patient enrollment in clinical trials.
At present, psychometric tests and severity rating scales
(i.e., Unified Parkinson’s Disease Rating Scale, UPDRS) are the de
facto standard for evaluating disease progression in PD. There is
however increasing interest in adopting longitudinal neuroimaging
techniques as adjunctive markers of disease progression with the
expectation that MRI measurements may provide better sensitivity
and precision than standard clinical measures (Jack et al., 2003;
Nestor et al., 2008; Schott et al., 2005). In this regard, advances in
neuroimaging analyses have contributed to the validation of whole-
brain atrophy rates (Smith et al., 2002) as sensitive markers of
disease progression in mild cognitive impairment (MCI; Sluimer
et al., 2010), frontotemporal dementia (Knopman et al., 2009),
and Alzheimer’s disease (AD; Fox and Freeborough,1997;Mak et al.,
2015b). In addition, ventricular enlargement has emerged as
another viable surrogate but not nonspecific marker of neuro-
degeneration in MCI and AD (Ferris et al., 2009; Jack et al., 2004;
Nestor et al., 2008). Instead of a mere proxy of widespread tissue
loss, ventricular enlargement has been linked to a broad range of
cognitive and memory deficits, reduced brain reserve against
neurodegeneration (Cavedo et al., 2012), and decreased survival in
dementia (Olesen et al., 2011).
Power calculations in MCI and AD have consistently shown that
whole-brain atrophy and ventricular enlargement would require
far smaller sample sizes (approximately 3e10 times reduction)
compared with cognitive tests to show differences from controls
(Jack et al., 2004; Ridha et al., 2008). This has significant implica-
tions on the design of early-intervention and secondary prevention
trials that are often hampered by subtle disease-related decline in
the prodromal stages (i.e., weak effect sizes) and greater uncer-
tainty that participants are on course for developing dementia
(i.e., greater variance in measurements). As a result, these trials
would require very long follow-up duration as well as large samples
to detect any disease-modifying effects.
Therefore, it is surprising that there are only limited studies
investigating the utility of whole-brain atrophy and ventricular
enlargement in PD.While increasedwhole-brain atrophy rates have
been reported in PD-D comparedwith controls (Burton et al., 2005),
it remains to be established if MRI-derived measurements of global
atrophy are sensitive to changes in a prodromal stage such as
PD-MCI, and whether these measurements are feasible in a clinical
trial targeting cognitive symptoms in PD. Ventricular enlargement
has also been less studied in PD (Camicioli et al., 2011) despite its
associations with both motor and cognitive impairment
(Apostolova et al., 2012).
Levels of CSF markers have been shown to be promising
candidate markers in AD (Blennow and Hampel, 2003; Frisoni et al.,
2010) and more recently in PD (Kang et al., 2016). Elucidating the
potentially unique role of each CSF marker in the later events of
neurodegeneration (i.e., structural atrophy) will have important
implications for informing strategies targeting the underlying
protein pathologies. In a pooled sample of PD patients, both CSF
T-Tau and Ab levels have been cross-sectionally associated with
lateral ventricular size (Beyer et al., 2013), whereas there are only
limited studies investigating the involvement of CSF markers and
progressive atrophy in PD (Compta et al., 2013).
To address the aforementioned gaps in the literature, we un-
dertook a new study with 3 main objectives: (1) to investigate the
suitability of global longitudinal measurements of brain volume
(whole-brain atrophy and ventricular enlargement) to monitor
disease progression over 18 months in newly-diagnosed PD
patients; (2) to evaluate the relationships between baseline CSFmarkers of neurodegeneration (a-synuclein, tau-protein) and
structural changes on imaging using tensor-based morphometry;
and (3) to assess the impact of using MRI measurements on future
clinical trials in nondemented PD patients by estimating the sample
sizes needed to detect a 20%e50% reduction in whole-brain atro-
phy, ventricular enlargement, and global cognition.
2. Method
2.1. Participants
The Incidence of Cognitive Impairment in Cohorts with Longi-
tudinal Evaluation-PD is a longitudinal observational study with
2 centers (Newcastle and Cambridge) to understand the disease
mechanisms underlying the evolution of PD-D from disease onset
(Yarnall et al., 2014). Patients were recruited from community and
outpatient clinics in the North East of England. In this study, we
included PD subjects (n ¼ 104) and healthy controls (n ¼ 38) who
completed baseline and follow-up clinical and T1 MRI imaging at
18 months. PD was diagnosed according to the UK Brain Bank
criteria by a movement disorders specialist (Hughes, 2002). Full
inclusion and exclusion criteria have been previously described
(Yarnall et al., 2014); patients were excluded at baseline if they had
a clinical diagnosis of PD-D or scored<24 on theMinieMental State
Examination. The study was approved by the Newcastle and North
Tyneside Research Ethics Committee. All subjects provided written
informed consent.
2.2. Clinical and neuropsychological assessment
Clinical assessments were performed by trained examiners and
included a standardized neurological examination and rating
disability with the Movement Disorders Society (MDS; UPDRS III;
Goetz et al., 2008), and Hoehn and Yahr (H&Y) staging (Hoehn and
Yahr, 2001). In accordance with MDS Task Force recommendations
(Litvan et al., 2012), 5 cognitive domains were assessed: attention
was measured using the Cognitive Drug Research computerized
battery (Wesnes et al., 2002). Mean response times of simple re-
action time, choice reaction time, and digit vigilance were summed
to produce a Power of Attention score. Digit vigilance accuracy was
also evaluated as part of this domain. Memory was assessed with
pattern recognition memory, spatial recognition memory, and
paired associates learning from the computerized Cambridge
Neuropsychological Test Automated Battery (Fray and Robbins,
1996). Executive function was determined using the modified
“One Touch Stockings” (OTS) version of the Tower of London task
from the Cambridge Neuropsychological Test Automated battery,
phonemic fluency (words beginning with “F” in 1 minute) and
semantic fluency (animals in 90 seconds). The pentagon copying
item of theMMSEwas graded using a modified 0 to 2 rating scale as
a measure of visuospatial function (Williams-Gray et al., 2009).
Language domain was assessed using the naming (0e3) and
sentence (0e2) subsets of the MoCA test. All participants were
assessed while they were on their usual dopaminergic medication
at baseline and 18 months. Levodopa equivalent daily dose (LEDD)
value was calculated using the Tomlinson et al. formula (Tomlinson
et al., 2010). Global cognitive function was assessed using the
MinieMental State Examination (MMSE) (Folstein et al., 1975) and
theMontreal Cognitive Assessment (MoCA; Dalrymple-Alford et al.,
2010). As our schedule of neuropsychological tests preceded the
introduction of the MDS criteria for PD-MCI, we used a modified
MDS level II criteria as described previously (Lawson et al., 2016;
Yarnall et al., 2014), in that only 1 test (i.e., pentagon copying)
was specific to the visuospatial domain. A subject was diagnosed as
PD-MCI if he or she performed 1.5 standard deviations (SDs) or
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2 neuropsychological tests across 5 cognitive domains: attention,
memory, executive function, language, and visuospatial function. To
reduce the number of comparisons, we derived a composite Z-score
for each domain based on the average of the Z-scores across the
respective tests. Using this cut-off, 38 PD subjects were classified as
PD-MCI, whereas the remaining 66 PD subjects were classified as
PD-NC. We classified participants as amnestic (n ¼ 26) or non-
amnestic PD-MCI (n ¼ 12) at baseline. Amnestic participants were
impaired in at least 2 tests across the 5 domains with at least
1 impaired memory test, whereas nonamnestic PD-MCI partici-
pants did not have impaired memory.
2.3. Lumbar puncture
At baseline, lumbar puncture was performed on a subset of PD
subjects (n ¼ 35) between 8 and 10 AM after an overnight fast and
while withholding PD medications as described (Yarnall et al.,
2014). Samples were centrifuged (2000 g, 4 C, 10 minutes)
within 15 minutes of collection and frozen at 80 C in
polypropylene cryovials until analyzed for b-amyloid 1e42 and
1e40 (Ab42 and Ab40), T-Tau, P-Tau, and total a-synuclein levels.
Based on previous evidence that the combined ratio of Ab42/Ab40
is a more precisemarker of Ab pathology than Ab42 and Ab40 alone
(Janelidze et al., 2016; Koyama et al., 2012), we derived a ratio of
Ab42/Ab40 for subsequent correlational analyses. The total PD
sample with CSF measurements was stratified into low and normal
Ab42 groups using a median split (948 pg/mL).
2.4. MRI acquisition and image analyses
Subjects underwent baseline and repeat MR imaging after
18months. BothMRI acquisitionswere performedwith the same 3T
MRI system (Intera Achieva scanner, Philips Medical Systems,
Eindhoven, Netherlands). The structural scans were acquired using
a standard T1-weighted volumetric sequence covering the whole
brain: 3D magnetization-prepared rapid gradient echo sequence,
sagittal acquisition, echo time (TE) ¼ 4.6 ms, repetition time
(TR) ¼ 9.6 ms, inversion time 1250 ms, flip angle ¼ 8, SENSE
factor¼ 2, in-plane field of view 240 240mmyielding a voxel size
of 1.15  1.15 mm with slice thickness of 1.2 mm.Fig. 1. Illustration of imaging pipeline for whole-brain atrophy rates and ventricular enlargem
changes between baseline and 18 months for each representative subject. Red indicates bra
ventricular percentage changes between baseline and 18 months after a ventricular ma
displacements. Abbreviation: VIENA, ventricular enlargement. (For interpretation of the ref
article.)2.5. Estimation of longitudinal whole-brain atrophy
Serial whole-brain atrophy was automatically estimated with
SIENA, a commonly used software package for measuring longitu-
dinal whole-brain atrophy that is distributed as part of the FSL
imaging suite (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/). The technical
details have been described (Smith et al., 2002, 2007). Briefly, for
each individual subject, the baseline and follow-up brain images
were aligned to each other using the skull images to constrain the
registration scaling, and both brain images were then resampled
into an intermediate halfway space with affine transformation.
Next, tissue-type segmentation was carried out to locate brain/
nonbrain edge points. The displacement of the follow-up brain
image comparedwith the baselinewas calculated as the edge-point
displacement perpendicular to the surface. Finally, the mean edge
displacement across the whole brain was converted into a global
estimate of percentage brain volume change (PBVC) between the
2 time-points (Fig. 1). The quality of the registrations across time
points, brain masks, and final outputs was then visually inspected
while blinded to diagnostic group information, during which
5 subjects were excluded (1 healthy control, 2 PD-MCI, and 2
PD-NC). SIENA has been shown to have 0.5% brain volume accuracy
in previous longitudinal studies (Smith et al., 2002).
2.6. Quantification of longitudinal ventricular enlargement
In addition, a recently validated technique (VIENA) was used to
measure the percentage of ventricular volume change over
18 months. The technical details for this procedure have been
described at length in the validation paper (Vrenken et al., 2014). In
summary, the average edge displacement was calculated on edge
points along the ventricular boundaries. This step made use of a
ventricular mask, in MNI152 space, of a single MS patient with
exceptionally large ventricles. The ventricular mask was then
linearly registered to each individual MRI. Finally, the average
ventricular edge displacement between both time-points was
converted into a summary value (Fig. 1). This technique has been
found to showa high agreement withmanual measurements with a
concordance correlation coefficient (CCr) >0.8 (Vrenken et al.,
2014). The whole process took only 10e20 minutes per subject,
rendering it practically convenient for large data sets.ent over time. (A) Whole-brain atrophy as quantified by SIENA. Each image shows the
in volume increase, whereas blue represents atrophy. (B) VIENA was used to calculate
sk (red pixels) were registered to each individual MRI to identify ventricular edge
erences to color in this figure legend, the reader is referred to the Web version of this
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We performed a voxel-wise estimation of regional tissue change
from the deformation field required to warp a subject’s follow-up
image to his/her baseline. We used the SPM output of divergence
rate as the measure of volumetric expansion/contraction
(Ashburner and Ridgway, 2013). The divergence rate images were
spatially normalized and smoothed with an 8-mm Gaussian kernel.
A voxel-wise general linear model was then used to investigate
regional volumetric correlations with T-Tau and P-Tau, covarying
for age, gender, and LEDD. Results were thresholded at p ¼ 0.001
uncorrected for multiple comparisons, and clusters reported as
significant at p < 0.05; family-wise error corrected.
2.8. Statistical analyses
Statistical analyses were performed with the STATA13 (http://
www.stata.com/) software. The distribution of continuous vari-
ables was tested for normality using the Skewness-Kurtosis test and
visual inspection of histograms. Parametric data were assessed
using either T-tests or analysis of variance for continuous variables.
For nonparametric data, Wilcoxon rank-sum or Kruskal-Wallis tests
were used. c2 tests were used to examine differences between
categorical variables. Effect sizes are reported in terms of eta2 and
Cohen’s D where appropriate. Partial correlations with relevant
covariates were performed to examine associations of imaging
changes (whole-brain atrophy and ventricular enlargement) with
cognitive/clinical measures and CSF markers. To determine
whether the associations between CSF markers and neuro-
degeneration are affected by baseline amyloid burden, we classified
the PD subjects into low and normal levels of CSF Ab42 based on a
median split. The mean concentration of CSF Ab42 in the low group
was 706.7 pg/mL, roughly in linewith previous cut-off values of 700
pg/mL in AD (Lehmann et al., 2014). For each test statistic, a 2-tailed
probability value of <0.05 was regarded as significant.
2.9. Sample size estimates for clinical trials
To investigate the impact of whole-brain atrophy and ventric-
ular enlargement on clinical trial designs in nondemented PD, we
performed sample size calculations with 80% power to detect a
20%e50% reduction in whole-brain atrophy, ventricular enlarge-
ment or MMSE (5% type I error, 2-tailed significant test p < 0.05).
Sample size was calculated using the conventional equation in
previous studies (Fox et al., 2000; Schott et al., 2010):
Sample size per arm ¼ ðuþ vÞ
22s2

D2
where s2 denotes the variance of outcome measure estimated in
the PD-MCI group, u¼ 0.84 to provide 80% power; v¼ 1.96 to test at
the 5% significance level, D ¼ estimated treatment
effect ¼ (0.2e0.5)  estimated whole-brain atrophy/ventricular
enlargement/MMSE decline in the PD-MCI group across 18 months.
Sample sizes were not derived for PD-NC since there were no sig-
nificant differences in imaging outcomes compared with healthy
controls.
3. Results
3.1. Sample characteristics
The demographic and clinical information for PD and control
subjects are summarized inTable1. PD-MCI subjectswere significantly
older than PD-NC (p ¼ 0.001), although there were no significantdifferences in age and gender between PD-MCI and healthy controls,
or between PD-NC and healthy controls. As expected, PD-MCI scored
significantly lower on both MMSE and MoCA compared with PD-NC
(p < 0.001) and healthy controls (p < 0.001).
3.2. Comparisons of percentage brain volume change and
ventricular enlargement
The extent of atrophy occurring between the baseline and
follow-up scan was expressed as a negative percentage of PBVC
(Fig. 2). ANCOVA revealed that PBVC was significantly different
betweengroups [F(2,130)¼ 9.6,p< 0.01; eta2¼0.13] after accounting
for age, gender, education, and scan-intervals. Post hoc Tukey-Kramer
tests revealed significantly greater percentage atrophy in PD-MCI
compared with healthy controls and PD-NC groups (p < 0.01),
although there were no differences in PBVC between PD-NC and
controls (p ¼ 0.99). After accounting for LEDD dosage, percentage
atrophy was still significantly higher in PD-MCI compared with PD-
NC (p < 0.01). Stratification of PD-MCI into amnestic (n ¼ 25) and
nonamnestic (n ¼ 12) subgroups at baseline revealed that only the
MCI-amnestic group showed increased whole-brain atrophy
compared with controls and PD-NC (p < 0.01). In addition, the MCI-
amnestic group also showed increased whole-brain atrophy
compared with nonamnestic group (p ¼ 0.048). Consistent with the
PBVC comparisons, there was a main effect of group on ventricular
enlargement [F(2,130)¼ 7.1, p< 0.01; eta2¼ 0.10]. The PD-MCI group
showed increased percentage of ventricular enlargement relative to
controls (p ¼ 0.04) and PD-NC (p < 0.01). Stratified comparisons at
baseline also showed that only the MCI-amnestic group had greater
percentage of ventricular enlargement relative to healthy controls
(p ¼ 0.016) and PD-NC (p < 0.01).
Regarding the comparisons between PDconverters and PDstable,
there were no significant differences in age, gender, education,
UPDRS, and duration of illness between both PDconverters and
PDstable. Although whole-brain atrophy was numerically greater in
PDconverters (0.5%  0.7%) compared with PDstable (0.4%  0.5%),
this difference was not significant (Student t test; p ¼ 0.44, Cohen’s
d ¼ 0.2). However, PDconverters showed a significant increase
in ventricular enlargement over 18 months compared with the
PDstable group (Student t test; p ¼ 0.015, Cohen’s d ¼ 0.7;
Supplementary Fig. 1).
3.3. Correlations of imaging outcome measures with clinical and
cognitive functions
In the overall nondemented PD sample, we investigated the
correlations of PBVC and ventricular enlargement over 18monthswith
global cognition and cognitive domains (Fig. 3). After accounting for
age, gender, and LEDD, partial correlations revealed a positive associ-
ation of PBVC with global cognition as assessed using the MoCA at
baseline (r¼ 0.23, p¼ 0.03) aswell as at follow-up (r¼ 0.24, p¼ 0.02),
although there was no significant correlation with % change of MoCA
change over 18 months (r ¼ 0.1, p ¼ 0.44). With respect to the MDS
cognitive domains, PBVC were significantly associated with the mem-
ory domain at baseline (r ¼ 0.38, p < 0.01) and follow-up (r ¼ 0.24,
p ¼ 0.02), but not with change over 18 months (r ¼ 0.15, p ¼ 0.14).
Ventricular enlargement over 18 months was highly correlated
with poorer MoCA at baseline (r ¼ 0.35, p  0.01) and follow-up
(r ¼ 0.31, p < 0.01). It was also associated with poorer perfor-
mance in various MDS cognitive domains at baseline, including
attention (r ¼ 0.25, p ¼ 0.02), memory (r ¼ 0.36, p < 0.01), and
executive function (r ¼0.22, p ¼ 0.035). At 18 months, ventricular
enlargement was also associated with attention (r ¼ 0.21,
p ¼ 0.04), memory (r ¼ 0.32, p < 0.01), executive function
(r ¼ 0.33, p < 0.01), and language (r ¼ 0.21, p ¼ 0.04). With
Table 1
Demographics and clinical characteristics
Subject groups HC PD-NC PD-MCI p
n 37 64 36
Age (y) 65.7  7.2 62.8  10.0 68.7  8.7 0.01b
Age range 49.7e85.4 41.8e87.3 48.1e85.5
Gender (male, %) 21, 56.8% 40, 63% 26, 72.2% 0.4a
Education (y) 13.9  3.9 13.8  3.6 11.3  3.3 <0.001f
Disease duration (mo) 24.2  4.7 24.7  5.4 0.8g
LEDD (mg/d) baseline 144.5  111.7 248.6  158.1 0.001g
H&Y baseline 1.9  0.7 2.1  0.6 0.054h
H&Y follow-up 2.1  0.6 2.2  0.4 0.2g
UPDRS III baseline 25.0  11.0 29.4  10.5 0.051h
UPDRS III follow-up 31.4  12.6 38.6  10.0 0.001g
MMSE baseline 29.4  1.0 29.1  0.8 28.1  1.4 <0.001b,c,d, 0.4e
MMSE follow-up 29.6  0.9 29.2  1.0 27.4  1.9 <0.001b,c,d, 0.2e
MoCA baseline 27.6  2.2 26.9  2.4 22.9  3.9 <0.001b,c,d, 0.4e
MoCA follow-up 27.9  3.0 27.8  2.1 24.1  3.6 <0.001b,c,d, 0.9e
Cognitive domainsg
Memory 0.2  0.7 2.0  1.6 <0.001
Memory follow-up 0.5  1.0 2.3  1.5 <0.001
Attention 0.1  0.6 1.6  2.0 <0.001
Attention follow-up 0.4  0.9 2.1  2.1 <0.001
Executive 0.2  0.6 1.2  0.9 <0.001
Executive follow-up 0.02  0.8 1.2  1.0 <0.001
Language 0.05  0.7 0.5  1.0 <0.01
Language follow-up 0.1  0.7 0.3  0.9 <0.01
Visuospatial 0.2  0.5 0.8  2.1 <0.001
Visuospatial follow-up 0.2  1.2 1.8  3.0 <0.001
Values expressed as mean  SD.
Key: GDS, Geriatric Depression Scale; H&Y, Hoehn and Yahr;MMSE, MinieMental State examination; MOCA,Montreal Cognitive Assessment; PD-MCI, Parkinson’s diseasewith
mild cognitive impairment; PD-NC, Parkinson’s disease with no cognitive impairment; UPDRS III, Unified Parkinson’s Disease Rating Scale, Part III.
a cAeAbbrev; PD-MCI, controls.
b ANOVAeHealthy controls, PD-NC, PD-MCI; Post hoc Tukey pairwise tests.
c PD-MCI versus healthy controls.
d PD-MCI versus PD-NC.
e PD-NC versus healthy controls.
f Kruskal-Wallis test.
g Wilcoxon rank-sum testePD-NC and PD-MCI.
h Student t testePD-NC and PD-MCI.
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ment was correlated with worsening executive function (r¼0.26,
p ¼ 0.01).
In terms of clinical features, UPDRS3 at follow-up was correlated
with ventricular enlargement (r ¼ 0.28, p ¼ 0.01) and whole-brain
atrophy (r ¼ 0.20, p ¼ 0.04) but not at baseline or change
over time.3.4. Correlations of global atrophy and ventricular enlargement
with CSF markers
There were no significant differences in age, gender, MMSE,
PBVC, and ventricular enlargement between the subset of PD pa-
tients with CSF samples (n ¼ 35) compared with the rest of the PD
group (n ¼ 65), although disease duration was significantly shorter
in those who underwent lumbar puncture (p < 0.01). The mean
concentrations of the CSF measurements are described in Table 2.
We investigated the correlations of imaging outcome measures
with CSF markers using partial correlation tests, accounting for age,
gender, LEDD, and disease duration (Fig. 4). Increased whole-brain
atrophy rates were associated with elevated baseline levels of T-Tau
(r ¼ 0.40, p ¼ 0.03) but not with AB42/Ab40 ratio (r ¼ 0.30,
p ¼ 0.11). Increased ventricular enlargement over 18 months was
significantly correlated with a lower Ab42/Ab40 ratio (r ¼ 0.38,
p ¼ 0.03), although a trend was observed with greater T-Tau levels
(r ¼ 0.35, p ¼ 0.06). We did not find any significant correlations
between CSF a-synuclein and PBVC (r ¼ 0.12, p ¼ 0.51) or ventric-
ular enlargement (r ¼ 0.13, p ¼ 0.50).Stratified correlations according to low and normal levels of CSF
Ab42 revealed that significant relationships between MRI and CSF
markers were predominantly driven by the low Ab42 group
(Supplementary Fig. 1). T-Tau was correlated with PBVC (r ¼ 0.67,
p ¼ 0.01) and VIENA (r ¼ 0.62, p ¼ 0.02), whereas Ab42/Ab40 ratio
was associated with PBVC (r¼ 0.58, p¼ 0.04) and VIENA (r¼0.75,
p< 0.01). Notably, these relationships were not found in the normal
CSF Ab42 group.
3.5. Associations of regional volumetric changes with CSF markers
We used tensor-based morphometry to further investigate the
associations of CSF T-Tau and P-Tau with localized volumetric
brain changes. There were trend-level clusters in the right tem-
poral lobe white matter where increased CSF T-Tau (p ¼ 0.065)
and P-Tau (p ¼ 0.055) correlated with tissue contraction over
time (Fig. 5).
3.6. Sample size calculations
Calculations for sample sizes are summarized in Fig. 6. Both
whole-brain atrophy and ventricular enlargement required sub-
stantially smaller sample sizes compared with global cognitive
decline (MMSE) for detecting significant differences over time in
PD-MCI patients versus controls. To detect a 20% reduction, 186 and
223 patients per arm are required for whole-brain atrophy and
ventricular enlargement respectively. In contrast, 2974 patients per
arm are required to detect an equivalent degree of slowing of global
Fig. 2. Box-and-whisker plots for comparisons of PBVC and ventricular enlargement for each group over 18 months. Negative % represents a decrease in volume over time.
Differences between groups were assessed by using ANCOVA controlling for age, gender, education, inter-scan interval, and LEDD, with post hoc Tukey-Kramer tests.
(A) Whole-brain atrophy was greater in PD-MCI compared with both PD-NC and HC (B) Only the amnestic subgroup of PD-MCI showed increased whole-brain atrophy compared
with PD-NC, HC, and non-amnestic PD-MCI. (C, D) Ventricular enlargement was greater in PD-MCI compared with PD-NC and healthy controls, particularly in the amnestic
subgroup of PD-MCI. Abbreviations: Amn, amnestic; HC, healthy controls; NON-amn, non-amnestic; PBVC, percentage brain volume change; PD-MCI, Parkinson’s disease with mild
cognitive impairment; PD-NC, Parkinson’s disease with no cognitive impairment; VIENA, ventricular enlargement.
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PD-NC because there were no significant differences compared
with controls in both imaging measurements.
4. Discussion
4.1. Main findings
We performed a longitudinal study to investigate whole-brain
atrophy and ventricular enlargement over 18 months in the
ICICLE cohort of nondemented PD. First, MRI measurements of
whole-brain atrophy and ventricular enlargement were signifi-
cantly increased in the PD-MCI group, particularly in patients with
memory impairment. Second, both global imaging markers were
associated with several cognitive domains as well as CSF markers of
AD pathology. Finally, sample size calculations showed that MRI
measurements would be more sensitive than neuropsychological
assessments to detect treatment effects in clinical trial. These
collective findings provide reasonable support for the use of im-
aging measurements as surrogate markers in early interventional
trials that target cognitive aspects of PD.
4.2. Increased whole-brain atrophy and ventricular enlargement in
PD-MCI
The literature on progressive whole-brain atrophy in PD is still
inconclusive. Increased atrophy rates in nondemented PD have
been reported in 1 study (Hu et al., 2001), but not in others(Burton et al., 2005; Guevara et al., 2016). These differences are
mostly ascribed to small sample sizes and heterogeneity in cogni-
tive profiles, especially as PD-MCI was not distinguished from PD-
NC. An earlier study that reported increased whole-brain atrophy
rates in PD involved a relatively small sample of PD patients (n ¼ 8)
whowere impaired inmemory and visuospatial functions (Hu et al.,
2001), both of which have been shown to herald subsequent pro-
gression to PD-D (Williams-Gray et al., 2009). In contrast, the PD
groups in the negative studies were not cognitively impaired at
baseline (Burton et al., 2005; Guevara et al., 2016). By stratifying our
analyses according to theMDS criteria for PD-MCI, our observations
of greater whole-brain atrophy may reconcile these inconsistencies
and provide further support for the conceptualization of PD-MCI as
a distinct clinical entity (Litvan et al., 2011)da necessary prereq-
uisite for enrichment of future clinical trials. Significant expansion
of the ventricles over 18 months was demonstrated in PD-MCI
compared with PD-NC and healthy controls. A previous 36-month
study only found increased ventricular enlargement in PD-D,
whereas nondemented PD did not differ from healthy controls
(Camicioli et al., 2011). Together, these longitudinal findings also
add to the limited body of cross-sectional evidence suggesting that
ventricular enlargement may be an early feature in prodromal PD-D
but not in PD-NC (Apostolova et al., 2010; Dalaker et al., 2011).
4.3. Amnestic PD-MCI is associated with greater neurodegeneration
Stratified analyses of the PD-MCI subgroups showed that
whereas whole-brain atrophy and ventricular enlargement were
Fig. 3. Scatter-plots showing the significant associations between whole-brain atrophy and ventricular enlargement with MDS cognitive domains in the total PD sample.
(A) PBVCememory, memory follow-up (B) VIENAeattention, attention follow-up (C) VIENAememory, memory follow-up (D) VIENAeexecutive function, executive follow-up, and
executive change. Abbreviations: MDS, Movement Disorders Society; PBVC, percentage brain volume change; VIENA, ventricular enlargement.
E. Mak et al. / Neurobiology of Aging 55 (2017) 78e9084significantly greater in the amnestic group, the nonamnestic sub-
type were not significantly different from healthy controls and
PD-NC, although both imaging measures were intermediate be-
tween PD-NC and PD-MCI amnestic groups. These discrepancies
may imply differential sites of pathology among various subtypes of
PD-MCI (Janvin et al., 2006), such that PD-amnestic individuals are
further along the path toward PD-D compared with their non-
amnestic counterparts. Similarly, it has been suggested that certain
cognitive domains are more predictive of dementia than others. The
“Dual Syndrome Hypothesis” distinguishes a relatively stable
fronto-striatal profile of impairment from “posterior cortical” defi-
cits (i.e., memory) that are associated with more pronounced
cholinergic deficits and increased progression to dementia (Kehagia
et al., 2012). An important caveat is that 22/25 of our amnestic PD-
MCI also had impairments in other domains (i.e., multi-domain
impairment). Future studies with larger sample sizes in each
group (single-nonamnestic/amnestic and multidomain-
nonamnestic/amnestic) would be needed to clarify the neurode-
generative profile associatedwith each cognitive subtypeof PD-MCI.4.4. Ventricular enlargement is associated with conversion to
PD-MCI
Longitudinal MRI studies may also be sensitive to early cogni-
tive decline in PD-NC. Camicioli et al. showed that ventricular
enlargementdmeasured using a volumetric approachdwas pre-
sent only in PD subjects who converted to PD-D over 36 months
(Camicioli et al., 2011). Our findings further demonstrated that
significant ventricular enlargement could be detected earlier in
PD-MCI over a shorter follow-up of 18 months. Notably, the
Cohen’s D effect size for increased ventricular enlargement (d ¼
0.7) in PD-NCconverters relative to PD-NCstable was substantially
larger compared with whole-brain atrophy (d ¼ 0.2), which did
not differ significantly between both PD-NC subgroups. Interest-
ingly, there is clinicopathological evidence to suggest that ven-
tricular enlargement is more strongly related to neuropathological
features of AD compared with whole-brain atrophy (Erten-Lyons
et al., 2013). Increased ventricular change has also been reported
in MCI patients who later converted to AD over 6 months
Table 2
Demographics, clinical, and imaging characteristics of the subset of PD sample with
CSF measurements
Subject groups PD, No CSF PD, CSF p value
n 68 35
PD-NC:PD-MCI 37:31 27:8
Age (y) 65.4  10 64.4  9.6 0.6c
Age range 41.8e85.5 47.8e87.3
Gender (male, %) 49, 72.1% 20, 57.1% 0.1a
Disease duration (mo) 25.7  0.6 21.9  0.5 <0.001b
UPDRS 27.3  11.1 25.7  10.8 0.6c
MMSE 28.6  1.3 28.97  1.0 0.2b
PBVC (%) 0.73  0.8 0.58  0.6 0.5b
Ventricular enlargement (%) 4.3  6.6 3.90  4.8 0.8b
CSF T-Tau (pg/mL) 130.1  102.8
CSF P-Tau (pg/mL) 48.1  20.7
CSF AB42 (pg/mL) 966.2  300.0
CSF AB40 (pg/mL) 10,968.3  4610.0
CSF AB42/AB40 ratio 0.10  0.03
CSF A-SYN (pg/mL) 92.4  49.0
PD, No CSF PD, CSF p value
n 65 35
PD-NC:PD-MCI 37:28 27:8
Age (y) 65.2  10.1 64.4  9.6 0.7c
Age range 41.8e85.5 47.8e87.3
Gender (male, %) 46, 71% 20, 57.1% 0.2a
Disease duration (mo) 25.8  5.2 21.9  3.1 <0.001b
UPDRS 27.1  11.1 25.7  10.8 0.5c
MMSE 28.6  1.3 29.0  1.0 0.2b
PBVC (%) 0.72  0.8 0.58  0.6 0.6b
VIENA (%) 4.2  5.6 3.1  4.3 0.3t
CSF T-Tau (pg/mL) 130.1  102.8
CSF P-Tau (pg/mL) 48.1  20.7
CSF Ab42 (pg/mL) 966.2  300.0
CSF Ab40 (pg/mL) 10,968.3  4610.0
CSF Ab42/Ab40 ratio 0.10  0.03
CSF a-synuclein (pg/mL) 92.4  49.0
Values expressed as mean  SD.
Key: CSF, cerebrospinal fluid; MMSE, MinieMental State Exam, PBVC, percentage
brain volume change; UPDRS, Unified Parkinson’s Disease Rating Scale III; VIENA,
ventricular enlargement.
a cD test.
b Wilcoxon rank-sum test.
c Student t test.
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using different approaches, may suggest that ventricular
enlargement is a viable marker for prodromal neurodegeneration
in PD.Fig. 4. Scatter plots showing significant associations between CSF markers (total tau and A
Abbreviations: PBVC, percentage brain volume change; VIENA, ventricular enlargement.4.5. Neuropsychological correlates of MRI measurements
The second objective of this study was to elucidate the clinical
relevance of both global MRI measurements. Whole-brain atrophy
was significantly associated with baseline and 18-month mea-
surements of global cognition and memory, whereas ventricular
enlargement showed additional correlations with multiple cogni-
tive domains as well as motor features. These correlations are in
broad agreement with previous studies in MCI and AD (Apostolova
et al., 2010; Jack et al., 2004; O’Brien et al., 2001; Sluimer et al.,
2008). Interestingly, ventricular enlargement was also associated
with longitudinal changes in executive function, an early PD feature
that is intimately linked with dopaminergic deficits in fronto-
striatal networks (Foltynie et al., 2004; Janvin et al., 2005).
These findings may suggest that ventricular enlargement, in
addition to being a sensitive state marker, shows promise in staging
cognitive decline, at least for those modulated by fronto-striatal
deficits in early nondemented PD. Several reasons could account
for the closer coupling of ventricular enlargement to a multitude of
clinical features, an observation that has also been reported in a
longitudinal multiple sclerosis study using both SIENA and VIENA
(the same imaging techniques employed in this study; Lukas et al.,
2010) as well as another clinicopathological study in AD (Erten-
Lyons et al., 2013). These include: (1) methodologically, the edge
displacement technique could bemore sensitive and accurate along
the smoother ventricular edges (VIENA) compared with the con-
voluted cortical folds (SIENA; Lukas et al., 2010); (2) alternatively,
ventricular enlargement may be a more dynamic measure over
time as subtle reductions of brain volume could result in relatively
larger expansions of the initially small ventricles (Anderson et al.,
2006; Erten-Lyons et al., 2013; Lukas et al., 2010); and (3) topo-
logically, ventricular enlargement could also be more functionally
relevant in the context of PD. The lateral and third ventricles are in
close proximity with subcortical structures, whereas the fourth
ventricle is situated within the pons andmedulla, both of which are
regions preferentially vulnerable to the ascending progression of
Lewy body pathology from the brainstem to the cerebral cortex
(Braak et al., 2004).4.6. Baseline CSF correlates of MRI measurements
The third objective of the study was to investigate these struc-
tural changes in relation to baseline CSF markers. Elevated CSF T-
Tau levels, rather than Ab42/Ab40, were correlated with increasedb42/Ab40 ratio) at baseline and MRI change measures (PBVC and VIENA) respectively.
Fig. 5. Correlations of T-Tau and P-Tau with volumetric changes over 18 months,
covarying for age, sex, and LEDD. Overlay on average of the group scans in MNI space,
crosshair at 41.5, 0, 25.5 mm. Thresholded at p < 0.001 uncorrected, min
cluster ¼ 200. Color bar represents t statistic. Abbreviations: LEDD, Levodopa equiv-
alent daily dose. (For interpretation of the references to color in this figure legend, the
reader is referred to the Web version of this article.)
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agreement with the literature showing an association between CSF
tau and brain morphological measures across PD (Beyer et al., 2013;
Compta et al., 2012), MCI, and AD (Solé-Padullés et al., 2011;
Thomann et al., 2009), and further implicate tau as an important
component of neurodegeneration in PD.
In our study, the correlations between ventricular enlarge-
ment and lower AB42/AB40 ratios are consistent with previous
findings looking at CSF (Beyer et al., 2013; Ott et al., 2010) and
[11C]-PiB PET imaging studies (Sarro et al., 2016). In one of the
largest MRI analyses of the ADNI cohort, Chou et al. showed that
ventricular enlargement correlated strongly with decreased CSF
Ab42 across healthy controls, MCI, and AD. However, the asso-
ciation of CSF tau with ventricular enlargement was less robust as
it did not persist after adjusting for covariates such as age (Chou
et al., 2009). Similarly, we found that CSF tau was only tended to
relate to ventricular enlargement. Ventricular enlargement,
particularly of the temporal horn, could well be associated with
adjacent atrophy in the medial temporal lobeda preferential site
of neurofibrillary tangle accumulation (Braak and Braak, 1995). In
the absence of in vivo localization of tau pathology, we can only
speculate that the CSF tau levels and measures of ventricular
expansion may be regionally specific (i.e., confined to the tem-
poral horn) and therefore lost when we consider global
percentage change over time. This suggestion also fits with our
tensor-based findings showing an association between CSFFig. 6. Necessary sample size per treatment arm using PBVC, VIENA, global cognitive decl
corresponding to 20%e50% reduction in the decline of the outcome measure, at 80% power,
change; PD-MCI, Parkinson’s disease with mild cognitive impairment; VIENA, ventricular etau levels and atrophy in overlapping regions of the temporal
lobe.
Could the relationships between CSFmarkers andMRI outcomes
be influenced by amyloid status? As discussed, our study did not
find an association between baseline CSF amyloid levels and lon-
gitudinal whole-brain atrophy although another study did find a
posterior pattern of cortical thinning in PD subjects with low CSF
Ab42 levels (Compta et al., 2013). These findings are not necessarily
in conflict with each other as a dichotomized amyloid status reflects
a cumulative marker of AD pathology, such that PD subjects with
low CSF Ab42 values are more likely to be further on course to
dementia. Methodological differences may also preclude direct
comparisons as cortical thickness was investigated in the Compta
et al. (2013) study. Indeed, there is evidence to suggest that
cortical thickness has the greatest sensitivity to neurodegeneration
in PD compared with other conventional structural MRI methods
(Pereira et al., 2012). Interestingly, when we stratified the PD sub-
jects according to a median split of CSF Ab42, only the low CSFAb42
group showed a significant association with both whole-brain at-
rophy and ventricular enlargement and CSF tau and Ab42/Ab40
ratio (Supplementary Fig. 2). These findings also are in line with a
recent tau PET study where the relationship between hippocampal
[18F]-AV1451 uptake and volume was only significant in amyloid-
positive subjects (Wang et al., 2016). These associations, confined
to individuals with increased amyloid burden, collectively fit a
model inwhich a pathological accumulation of amyloid is necessary
before triggering a cascade of downstream neurodegeneration (Jack
et al., 2013). The precise mechanisms for this process are still un-
known, although there is evidence that b-amyloid may convert tau
into its neurotoxic form, leading to cellular dysfunction and even-
tually cell death (Bloom, 2014).
4.7. CSF a-synuclein
The relationship between CSF a-synuclein levels and longitu-
dinal atrophy has been relatively understudied (Campbell et al.,
2015; Compta et al., 2014; Mattsson et al., 2013). In our present
study, CSF a-synuclein was not associated with whole-brain atro-
phy or with ventricular enlargement. This runs counter to previous
studies, where reductions in CSF a-synuclein have been shown to
correlate with functional deficits in motor networks (Campbell
et al., 2015) and frontal atrophy in nondemented PD (Compta
et al., 2014). Interestingly, Compta et al. observed a reverse rela-
tionship in the PD-D group, where increased CSF a-synuclein wasine in PD-MCI. Calculations were performed on the assumption of a treatment effect
and a 2-sided 0.05 level of significance. Abbreviations: PBVC, percentage brain volume
nlargement.
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cuneus, both of which are commonly implicated in preclinical and
established stages of dementia (Mak et al., 2017; Villemagne and
Chételat, 2016). However, the correlations did not persist after
adjusting for CSF tau, suggesting that any effects of CSF a-synuclein
may be mediated through tau (Compta et al., 2014). In agreement
with our study, a previous analysis involving the ADNI cohort also
found that baseline levels of CSF a-synuclein were not correlated to
atrophy brain rates across the spectrum of normal aging, MCI, and
AD (Mattsson et al., 2013). These findings, considered together with
autopsy-confirmed reports of relatively preserved brain structure
in Lewy body diseases (Nedelska et al., 2015), suggest that the ef-
fects of a-synuclein pathology may be mediated via cellular
dysfunction and functional network disruption (Peraza et al., 2015;
Rittman et al., 2016). These are important questions that will be
further addressed by the future development of PET radioligands
for a-synuclein (Eberling et al., 2013).
4.8. Lack of correlations between imaging changes and cognitive
decline
The breadth of findings in this study provides reasonable sup-
port for the use of imaging measures in clinical trials of non-
demented PD. However, despite evidence of correlations between
whole-brain atrophy and ventricular enlargement with cross-
sectional cognitive domains and CSF markers, only ventricular
expansion showed covariance with executive function over
18 months. This is surprising, as previous studies have reported
correlations between both global MRI summaries and cognitive
changes in PD-D and other neurodegenerative conditions
(Camicioli et al., 2011; Jack et al., 2008; Knopman et al., 2009).
Several explanations arise, including (1) the relatively stable tra-
jectories or evenminimal cognitive improvements in this PD cohort
as well as other parkinsonian conditions (Guevara et al., 2016); (2)
that the clinical assessments could fluctuate in response to other
influences that are unrelated to disease progression; (3) greater
cognitive reserve in highly functioning individuals may mask the
underlying disease progression; (4) the length of follow-up could
also be insufficient to detect cognitive decline, as other studies have
reported negligible cognitive decline in nondemented PD subjects
over 4 years (Aarsland et al., 2004); and (5) that our sample was
evaluated while taking dopaminergic medication, which has been
associated with both beneficial and adverse effects on executive
function in PD (Cools et al., 2001; Molloy et al., 2006). This is by no
means an exhaustive list of factors that could influence the vari-
ability in clinical and cognitive measurements, but it does highlight
the value of using adjunctive imaging markers in clinical trials.
4.9. Impact of MRI outcomes on clinical trials
Consistent with other studies in MCI and AD (Jack et al., 2003;
Ridha et al., 2008), we found that using cognitive testing (MMSE)
as a trial end point would require significantly more patients to
detect the same degree of treatment-related slowing of decline
compared with MRI measures. Nevertheless, the effect size on a
clinical scale may be differentially consequential compared to an
equivalent change on MRI (i.e., a 20% reduction in MMSE decline
may be more clinically meaningful compared with the same degree
of reduced atrophy rates). Therefore, we recommend that neuro-
imaging should still be used in conjunction with cognitive assess-
ments in trials designed to evaluate disease progression and the
effectiveness of disease modifying treatments. Several studies have
found that approximately 35e100 AD and 100e200 MCI patients
are necessary to detect a 25% reduction in brain atrophy (Beckett
et al., 2010; Ho et al., 2010; Hua et al., 2010; Nestor et al., 2008).Our findings extend these reports to PD-MCI, a condition for which
there are currently no disease-modification trials. Assuming a
clinical trial design with 18 months of follow up and a 20% absolute
reduction in volume loss, the required sample sizes for whole-brain
atrophy (n ¼ 186) and ventricular enlargement (n ¼ 223) are larger
than previous estimates in AD (n ¼ 115; Fox et al., 2000), in line
with the milder atrophy seen in PD or PD-D relative to AD (Beyer
et al., 2007; Burton et al., 2004; Mak et al., 2015a). Nevertheless,
these numbers are not prohibitive in terms of logistics and cost,
particularly for secondary preventive trials in PD-MCI patients.
Furthermore, the relationships of both imaging outcomes with AD
pathologiesdnot alpha-synucleindsuggest that patients with
Lewy body diseases might stand to benefit from interventions
directed against amyloid and tau pathologies. This will no doubt be
a topic for important validation using in vivo PET imaging of amy-
loid and tau in Lewy body diseases (Gomperts, 2016; Kantarci et al.,
2017; Sarro et al., 2016).
4.10. Strengths and limitations
The main strength of this prospective cohort study is its longi-
tudinal follow-up of an incident cohort allowing correlation of
longitudinal global atrophy in PD with cognitive function. The
comprehensive analyses of CSF enabled the investigation of the
differential correlation of each CSF marker to longitudinal atrophy,
an area of research that is currently understudied in PD. We used
validated approaches to measure longitudinal global changes
which reduces inter-subject variability as each subject serves as his
or her own control (Smith et al., 2007; Vrenken et al., 2014). There
are several practical benefits associated with global summaries
particularly in the context of large-scale clinical trials. These mea-
surements are fully automated, fast (20e30 minutes per subject),
and they have been shown to demonstrate high accuracy, high test-
retest reliability as well as robustness against different scanner
sequences (Smith et al., 2002). Compared with regional measure-
ments (e.g., bilateral hippocampus), the lateral ventricle is the most
consistently measured structure cash (Cash et al., 2015). This
reduction in variability is crucial for reducing sample sizes neces-
sary to detect a treatment effect. Several potential limitations
should be recognized. Subjects were assessed while taking their
medication, which could influence cognitive function and CSF
measures. To address this, we accounted for LEDD in all group
comparisons and correlational analyses. In the cognitive battery we
used, our assessment of visuospatial function was limited as we
only had 1 representative test. However, the pentagon copying item
of the MMSE has a high predictive value for the development of
dementia in PD (Garcia-Diaz et al., 2014; Williams-Gray et al.,
2007). In addition, the magnitude of the correlations between
imaging measures and cognitive domains were rather modest
despite the statistical significance. Many factors contribute to
cognitive decline. Some but not all of these will be expressed
through differences in brain structure, in addition to which the
imaging markers represent a greatly reduced dimensionality of
patients’ neural systems. Correction for multiple comparisons was
not performed in this study due to the intercorrelated nature of the
MDS cognitive domains and should be replicated in independent
cohorts. The extent and accuracy of longitudinal imaging mea-
surements may be influenced by baseline volumes too. For instance,
ventricular enlargement may be greater early in the disease when
the baseline volume is smaller. However, the methods used in this
paper are solely longitudinal, providing the amount of % change
between scans but not the initial volume at baseline (Vrenken et al.,
2014).While SIENA/VIENA do not permit cross-sectional volumetric
quantification, they use consecutive images at 2 time-points to
estimate the local displacements between edges from serial images.
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high test-retest reliability as well as robustness against different
scanner sequences (Smith et al., 2002). Furthermore, the accuracy
of VIENA is not affected by the initial ventricular volume (manually
segmented; Vrenken et al., 2014). In addition to greater processing
time and demands, volume-based quantification typically require
MR images with good intensity contrasts between gray and white
matter, which may be decreased in aging. Such requirements may
not always be satisfied in large-scale clinical trials or are unavailable
in retrospective studies from archived images.
5. Conclusion
In summary, we found that global atrophy and ventricular
enlargement, estimated using fully automated and less labor-
intensive approaches are sensitive to disease progression by way
of group-differences between PD-NC and PD-MCI. These MRI
markers could be used to enrich for patient cohorts for clinical trials
of disease modifying therapies as more aggressive profiles of
whole-brain atrophy and ventricular enlargement are associated
with individuals who are more likely to demonstrate a significant
cognitive decline over the course of a clinical trial. Indeed we have
further shown that using both global MRI markers would require
much smaller sample sizes for trials compared with neuropsycho-
logical assessments to detect an equivalent degree of treatment
effects. However further studies are needed to show the utility of
this approach using independent cohorts of patients.
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